Chiusura precedente | 0,4000 |
Aperto | N/D |
Denaro | 0,0000 |
Domanda | 0,2500 |
Prezzo d'esercizio | 7,00 |
Scadenza | 2024-08-16 |
Min-Max giorno | 0,4000 - 0,4000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 20 |
ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upo
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: Citi’s 18th Annual BioPharma Conference (Boston). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Di
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data from TZIELD® (teplizumab-mzwv) type 1 diabetes study Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused